Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:43:17.945Z.
Calculation as of: 2026-10-06T19:43:17.945Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
PE RATIO
N/A
Market Cap
$210.90M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.35M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.80M
PE Ratio
N/A
TTM Avg
399.45
3Y Avg
399.45
5Y Avg
399.45
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $210.85M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.85M | 5.94 | 6.53 | 42.60 | 42.60 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $210.90M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.80M | N/A | 8.07 | 11.31 | 11.31 |
| Niagen Bioscience Inc (NAGE)vs › | $212.25M | 14.30 | 22.48 | 68.28 | 68.28 |
| Pro-Dex, Inc. (PDEX)vs › | $209.25M | 15.91 | 14.32 | 17.96 | 17.40 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.74M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A | 399.45 | 399.45 | 399.45 |
| Electra Therapeutics Inc. (ETRA)vs › | $205.44M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.67
Forward EPS (Est.)
$-2.48
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
